Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567656 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
A Phase 1 study of Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous, sponsored by Rhizen Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 8
- Study locations
NCT02567656 is a Phase 1 study of Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous that has completed, run by Rhizen Pharmaceuticals. The registered enrollment target is 58 participants, below the 323-participant average among 6 other Lymphoma, T-Cell, Peripheral trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT02567656, a Phase 1 study of Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous, has completed, sponsored by Rhizen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
Conditions Studied
Interventions
- DRUG RP6530
Study Locations (8)
California
- City of Hope - Duarte
- Chao Family Comprehensive Cancer Center University of California Irvine - Orange
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Karmanos Cancer Institute - Detroit
Colorado
- University of Colorado Cancer Center - Aurora
Georgia
- Emory University School of Medicine - Atlanta
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02567656
The ClinicalTrials.gov registry entry for NCT02567656 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 6 other Lymphoma, T-Cell, Peripheral trials with a reported enrollment target (82% lower). The listed sponsor is Rhizen Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, T-Cell, Peripheral appearing as the primary indexed condition, and to 1 intervention - of which RP6530 is the first listed.
NCT02567656 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Michigan, Colorado.
Frequently Asked Questions
What is clinical trial NCT02567656 about?
NCT02567656 is a clinical study titled "Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma". The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
What is the current status of trial NCT02567656?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2015-09. Estimated completion is 2018-12-10.
What conditions does trial NCT02567656 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous.
What interventions are being tested in trial NCT02567656?
The interventions under investigation include: RP6530 (DRUG).
Who is sponsoring clinical trial NCT02567656?
This trial is sponsored by Rhizen Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02567656 being conducted?
This trial has 8 study locations across California, Colorado, Georgia, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, T-Cell, Peripheral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
ACTIVE NOT RECRUITING · Phase 1
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
-
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
COMPLETED
-
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.